Hyperfine announced its first commercial sales of the next-generation Swoop portable MRI system, powered by proprietary Optive AI software, to two leading hospitals in the northeastern U.S. This follows FDA clearance received last month and marks a key step toward broader adoption of portable brain imaging.
The new Swoop system features enhanced image quality and faster acquisition times, driven by a high signal-to-noise ratio combined with Optive AI’s capabilities. Designed with patient and user experience in mind, it aims to serve a wide patient population.
Swoop remains the only FDA-cleared ultra-low-field portable brain MRI, with Hyperfine focused on expanding access and advancing imaging technology through AI and machine learning.
“This milestone reflects our seamless execution and growing customer interest,” said Hyperfine CEO Maria Sainz. “We anticipate strong growth in the second half of 2025 and beyond.”
Follow MEDWIRE.AI for latest AI innovations in neuroimaging.
